About HepCare Europe

Hepatitis C infection is a major cause of chronic liver disease and death throughout the world.  Approximately 3% of the world’s population is infected with hepatitis C virus (HCV).

In the last three years a medical revolution has seen the development of HCV drugs, called direct-acting antivirals, which can cure almost all those who receive an evaluation and treatment.  Treatment consists of one or two pills administered orally each day for a period of often just 12 weeks. The treatment has led to cures and reversals among those with advanced HCV-related liver disease.

The HepCare Europe project focuses on providing an ‘integrated care’ model for HCV treatment based on the joint participation of primary and speciality care practitioners to allow for more efficient use of limited specialist resources.

About HepCare Europe